Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,300.00
(
0.69%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.93
(
-0.72%
)
Bitcoin
74,134.53
(
0.26%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: poorgradstudent post# 120693

Friday, 05/27/2011 5:58:55 PM

Friday, May 27, 2011 5:58:55 PM

Post# of 257253
Re: AIM-HIGH musings

In the real world, things are not as tidy as in clinical trials. For instance, some users of Zetia, Tricor/TriLipix, and Niaspan are not at their LDL goal; although it seems more doubtful based on what we now know, for these users we can’t say for sure that adding an HDL-raising or TG-lowering agent does not help.

I presume from the post I’m replying to that you do not think the AIM-HIGH failure is bullish for AMRN.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now